Discussant panel

17 May 2025 (16:00 - 16:00)

Organised by:

6 More presentations in this session

Presentation thumbnail

Safety and tolerability of a 5 mg starting dose of vericiguat among patients with heart failure: the VELOCITY study

Professor S. Greene (Durham, US)

Presentation thumbnail

Cardiopulmonary exercise testing as a novel endpoint in clinical trials on ATTR amyloid cardiomyopathy

Doctor A. Porcari (London, GB)

Presentation thumbnail

Efficacy and safety of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms

Professor I. Olivotto (Florence, IT)

Presentation thumbnail

Pulmonary artery denervation clinical study using the gradient denervation system in heart failure patients with pulmonary hypertension group 2

Doctor J. Nunez Villota (Valencia, ES)

Presentation thumbnail

Hemodynamic effects of TX45 , a long-acting Fc-relaxin fusion, in Group 2 pulmonary hypertension patients.

Doctor A. Muslin (Watertown, US)

Access the full session

Session thumbnail

Late-breaking science in heart failure, cardiomyopathies, pulmonary hypertension and valvular heart disease

The Event

Event poster

Heart Failure 2025

17 May 2025 16:00 CET

You may be interested in

Congress Session

Bridging gaps in heart failure care: primary care trends, exercise, kidney function, and global health perspectives

Congress Session

Nursing and Allied Professions Investigator Award

Congress Session

The strength of scientific integration

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources